In menopause breast cancer tissues histologic selleck products grade I to III the positive rates of BCL-2 were 88.9%, 73.7%, 0.0%, and the rates of BAD were 61.1%, 68.4%, 33.3% statistical analysis both showed no significant difference, (P = NS). The positive rates of BCL-2 and BAD were all showed declining trend in the clinical TNM stage from I to IV of youth and menopause breast cancer tissues, but, the difference has no significance (P = NS). The positive rates of BCL-2 were 15.8% in the youth breast cancer tissues had axillary lymph nodes metastasis, the rates were 76.2% which had no axillary

lymph node metastasis(P < 0.01); But the positive rates of BAD showed no Selleck Volasertib relationship with the axillary lymph nodes metastasis. In the menopause breast cancer tissues the positive rates were 20.0% in the axillary lymph nodes metastasis group and 93.3% in control group(P < 0.01); The positive rates of BAD also showed no relationship with the axillary lymph node metastasis in menopause breast cancer tissues(P = NS) (Table 3). Table 3 The relationship

learn more between the expression of BCL-2, BAD and the histologic grade, clinical TNM stages and the axillary lymph nodes metastasis in youth and menopause breast cancer tissues   Total Histologic grade Clinical TNM stage Axillary lymph nodes     I II III I II III IV Positive Negative Youth breast cancer tissues 40 8 27 5 6 25 8 1 19 21 BCL-2+ 19 7 12 0 4 12 3 0 3 16 BCL-2- 21 1 15 5 2 13 5 1 16 5 +% 47.5% 87.5%1 44.4% 0.0% 66.7%3 48.0% 37.5% 0.0% 15.8%4 76..2% BAD+ 12 4 8 0 2 8 2 0 6 6 BAD- 28 4 19 5 4 17 6 1 13 15 +% 30.0% 50.0%2 29.6%

0.0% 33.3%3 32.0% 25.0% 0.0% 31.6%5 28.6% Menopause breast cancer tissues 40 18 19 3 5 22 11 2 10 30 BCL-2+ 30 16 14 0 4 17 8 1 2 28 BCL-2- 10 2 5 3 1 5 3 1 8 2 +% 75.0% 88.9%2 73.7% 0.0% 80.0%3 77.3% 72.7% 50.0% 20.0%4 93.3% BAD+ 25 11 13 1 4 15 6 0 5 20 BAD- 15 7 6 2 1 7 5 2 5 10 +% 62.5% 61.1%2 68.4% 33.3% 80.0%3 68.2% 54.5% 0.0% 50.0%5 66.7% Compare with each other in the same group:1: P < 0.01,2: P > 0.05,3: P > 0.05,4: P < 0.01,5: P > 0.05 2.1.4 Depsipeptide supplier The relationship between the expression of BCL-2, BAD and the expression of ER, PR All the breast cancer tissues in this study, 9 tissues with the expression of BCL-2 and BAD were positive;In this 9 tissues ER(+)PR(+) of 6 cases(66.7%), ER(+)PR(-) of 2 cases(22.2%), ER(-)PR(+) of 1 case(11.0%), ER(-)PR(-) was 0, When ER(+)PR(+) the positive co-expression rates of BCL-2 and BAD were significantly higher than the other three groups, there were significant differences (P < 0.05).